Intra-Cellular Therapies Total Assets 2013-2022 | ITCI

Intra-Cellular Therapies total assets from 2013 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Intra-Cellular Therapies total assets for the quarter ending March 31, 2022 were $0.869B, a 28.78% increase year-over-year.
  • Intra-Cellular Therapies total assets for 2021 were $0.49B, a 31.7% decline from 2020.
  • Intra-Cellular Therapies total assets for 2020 were $0.717B, a 185.57% increase from 2019.
  • Intra-Cellular Therapies total assets for 2019 were $0.251B, a 29.68% decline from 2018.
Intra-Cellular Therapies Annual Total Assets
(Millions of US $)
2021 $490
2020 $717
2019 $251
2018 $357
2017 $471
2016 $389
2015 $484
2014 $131
2013 $38
2012 $20
Intra-Cellular Therapies Quarterly Total Assets
(Millions of US $)
2022-03-31 $869
2021-12-31 $490
2021-09-30 $557
2021-06-30 $626
2021-03-31 $674
2020-12-31 $717
2020-09-30 $771
2020-06-30 $441
2020-03-31 $481
2019-12-31 $251
2019-09-30 $281
2019-06-30 $310
2019-03-31 $343
2018-12-31 $357
2018-09-30 $386
2018-06-30 $412
2018-03-31 $446
2017-12-31 $471
2017-09-30 $334
2017-06-30 $350
2017-03-31 $372
2016-12-31 $389
2016-09-30 $543
2016-06-30 $448
2016-03-31 $464
2015-12-31 $484
2015-09-30 $513
2015-06-30 $213
2015-03-31 $237
2014-12-31 $131
2014-09-30 $138
2014-06-30 $141
2014-03-31 $147
2013-12-31 $38
2013-09-30 $47
2013-06-30 $0
2013-03-31 $0
2012-12-31 $0
2012-09-30 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.459B $0.084B
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00